Therapeutic area data reported by biopharma companies on phase I trials in February 2020, including: Abeona, Actinium, Advaxis, Agenus, Apeiron, Aravive, Arrowhead, Aura, BMS, Celltrion, Ciclomed, Compugen, Corvus, Cyclo, Cytodyn, Cytomx, Exelixis, Faron, Freeline, Genetx, Genprex, Harbour, Immix, Incysus, Inflazome, Innovation, Ionctura, Iteos, Kodiak Sciences, Matinas, Mirati, Moderna, Moleculin, Neurimmune, Noxopharm, Ocular, Oxurion, Pandion, Phasebio, Regulus, Reneo, Restorbio, Sernova, Soricimed, Sorrento, Takeda, Transgene, Urovant.

Therapeutic area data reported by biopharma companies on phase II trials in February 2020, including: Aldeyra, Antibe, Azurrx, Bellerophon, Bioxcel, Brainstorm, Cassava, Cytodyn, Delmar, Dermata, Eisai, Eli Lilly, Fulcrum, Galderma, Galera, Immunicum, Immunogenx, Immutep, Ironwood, Lidds, Magenta, Menlo, Moderna, NGM, Nymox, Oculis, Oncoimmune, Oramed, Palatin, Ra, Reneuron, Roche, Sanofi, T3D, Teva, Theralase, Trovagene, United, Vascular, Vistagen, Zynerba.

Completed biopharma M&As, including: Achillion, Alexion, Altavant Sciences, Artara, Aspen Global, Astellas, Audentes, Carriergene, Novartis, Nuprobe Global, Onspira, Proteon, Synthorx, The Medicines Co.

According to an analysis conducted by BioWorld of the fourth-quarter and year-end 2019 financial reports filed by the top 100 public biopharmaceutical companies ranked by market cap, and excluding big pharma companies, the amount that was invested in research and development (R&D) during the year increased 35% compared to the same period in 2018.

The financial markets were delivered a one-two punch March 9 – a plunge in oil prices along with fears that the coronavirus is continuing to spread unabated. As a result, the Dow Jones Industrial Average cratered 1,500 points in early trading after a brief halt with market circuit breakers kicking in. Biopharma equities did not escape the carnage, with the BioWorld Biopharmaceutical index trading down about 4% by market close, with the Dow closing down 7.8%.